Moderna (NASDAQ:MRNA) Price Target Lowered to $99.00 at The Goldman Sachs Group

Moderna (NASDAQ:MRNA - Get Free Report) had its price objective lowered by stock analysts at The Goldman Sachs Group from $112.00 to $99.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. The Goldman Sachs Group's price target suggests a potential upside of 120.29% from the stock's previous close.

Other research analysts have also issued research reports about the stock. Evercore ISI dropped their price objective on shares of Moderna from $60.00 to $50.00 and set an "in-line" rating for the company in a report on Monday. UBS Group cut their target price on Moderna from $108.00 to $96.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. Needham & Company LLC reissued a "hold" rating on shares of Moderna in a research note on Friday, November 8th. Piper Sandler restated an "overweight" rating and set a $69.00 price objective (down from $115.00) on shares of Moderna in a research report on Monday, November 18th. Finally, Leerink Partners decreased their target price on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research report on Thursday, January 16th. Four equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $69.79.

Moderna Price Performance

NASDAQ:MRNA traded up $3.29 on Tuesday, hitting $44.94. The company had a trading volume of 13,257,090 shares, compared to its average volume of 12,854,136. The firm has a 50 day moving average of $40.79 and a two-hundred day moving average of $62.18. The stock has a market capitalization of $17.29 billion, a price-to-earnings ratio of -7.72 and a beta of 1.60. Moderna has a 52 week low of $31.94 and a 52 week high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts' consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company had revenue of $1.90 billion during the quarter, compared to analysts' expectations of $1.25 billion. During the same period in the prior year, the company earned ($1.39) EPS. Moderna's revenue was up 3.8% compared to the same quarter last year. On average, research analysts anticipate that Moderna will post -9.27 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares in the company, valued at $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last ninety days, insiders sold 2,664 shares of company stock valued at $115,210. Corporate insiders own 15.70% of the company's stock.

Institutional Investors Weigh In On Moderna

Institutional investors have recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB raised its stake in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after purchasing an additional 587 shares during the period. MassMutual Private Wealth & Trust FSB increased its holdings in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after buying an additional 389 shares during the last quarter. Blue Trust Inc. raised its position in Moderna by 53.1% in the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock worth $47,000 after acquiring an additional 388 shares during the period. EMC Capital Management boosted its stake in Moderna by 311.2% in the fourth quarter. EMC Capital Management now owns 1,250 shares of the company's stock valued at $52,000 after acquiring an additional 946 shares during the last quarter. Finally, Larson Financial Group LLC increased its stake in shares of Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company's stock worth $61,000 after purchasing an additional 317 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.